AR068409A1 - Composiciones farmaceuticas, transdermicas sin alcohol - Google Patents
Composiciones farmaceuticas, transdermicas sin alcoholInfo
- Publication number
- AR068409A1 AR068409A1 ARP080103942A ARP080103942A AR068409A1 AR 068409 A1 AR068409 A1 AR 068409A1 AR P080103942 A ARP080103942 A AR P080103942A AR P080103942 A ARP080103942 A AR P080103942A AR 068409 A1 AR068409 A1 AR 068409A1
- Authority
- AR
- Argentina
- Prior art keywords
- agents
- composition
- dermal
- active agent
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
Abstract
Composicion de administracion transdérmica de fármacos sin alcohol administrada mediante un dispositivo de dosificacion de fármacos de nebulizacion medida. La composicion de dosificacion transdérmica de fármacos se administra a una superficie dérmica o mucosa de un animal que necesita la misma usando un dispositivo de nebulizacion medida capaz de dosificar una nebulizacion fina de un tamano de partículas sustancialmente uniforme para minimizar el tiempo de secado requerido de la misma. Reivindicacion 1: Una composicion sin alcohol que comprende: una cantidad eficaz de uno o más agentes fisiologicamente activos; una cantidad eficaz de uno o más potenciadores de la penetracion transdérmica seleccionados entre el grupo que consiste en éteres de dietilenglicol y filtros solares de éster; y uno o más líquidos no volátiles en una composicion sin alcohol. Reivindicacion 3: La composicion de la reivindicacion 1 en la que dichos agentes activos se seleccionan entre el grupo que consiste en androgenos, anti-androgenos, estrogenos, anti-estrogenos, progestogenos, anti-progestogenos, agonistas, adrenérgicos, analgésicos, sedantes, amidas, arilpiperazinas, agentes nerviosos, antineoplásicos, agentes antiinflamatorios, anticolinérgicos, anticonvulsionantes, antidepresivos, antiepilépticos, antihistamínicos, antihipertensivos, relajantes musculares, diuréticos, broncodilatadores y glucocorticoides. Reivindicacion 4: La composicion de la reivindicacion 1 en al que dichos agentes activos se seleccionan entre el grupo que consiste en agentes alimentarios, agentes cardiovasculares, agentes sanguíneos y hemopoyéticos, agentes del sistema nervioso central, agentes musculoesqueléticos, hormonas, esteroides, agentes genitourinarios, antimicrobianos, agentes del metabolismo, agentes para alergias y del sistema inmune y agentes respiratorios. Reivindicacion 6: La composicion de la reivindicacion 1 en la que dichos potenciadores de la penetracion transdérmica se seleccionan entre el grupo que consiste en potenciadores de la penetracion de filtros solares de éter, monoalquil C1-6 éteres de dietilenglicol, derivados de laurocapram, derivados de laurocapram, ácido oleico y sus derivados de éster, ésteres de sorbitán, ésteres de ácidos grasos, ésteres de 2-pirrolidona y 2-n-nonil-1-3-dioxolano. Reivindicacion 56: Una composicion de dosificacion transdérmica de fármacos no oclusiva que comprende: (i) una cantidad terapéuticamente eficaz de al menos un agente fisiologicamente activo; (ii) al menos un potenciador de la penetracion dérmica, que está presente en una cantidad del 10 al 10.000% en peso basándose en el peso total del agente activo; (iii) al menos un líquido no volátil presente en una cantidad para actuar como vehículo para el agente activo y el potenciador de la penetracion;.donde: el potenciador de la penetracion dérmica (A) se adapta para transportar al agente fisiologicamente activo a través de una superficie dérmica o mucosa de un animal, cuando el líquido no volátil se evapora, para formar un reservorio o deposito de una mezcla que comprende el potenciador de la penetracion y el agente fisiologicamente activo dentro de dicha superficie o membrana, y (B) se tolera por la superficie dérmica o mucosa del animal; y después de la administracion de la composicion a un área de la superficie dérmica o mucosa, el área se vuelve seca a los 4 minutos de la aplicacion. Reivindicacion 65: Una composicion de acuerdo con la reivindicacion 56, que comprende adicionalmente un agente de composicion farmacéutica, codisolvente, tensioactivo, emulsionante, antioxidante, conservante, estabilizante, diluyente o una mezcla de dos o más de dichos componentes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99387407P | 2007-09-14 | 2007-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR068409A1 true AR068409A1 (es) | 2009-11-18 |
Family
ID=40452524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103942A AR068409A1 (es) | 2007-09-14 | 2008-09-11 | Composiciones farmaceuticas, transdermicas sin alcohol |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090098069A1 (es) |
AR (1) | AR068409A1 (es) |
CA (1) | CA2699630A1 (es) |
CL (1) | CL2008002720A1 (es) |
PE (1) | PE20091011A1 (es) |
WO (1) | WO2009036311A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004227853A1 (en) | 2003-04-02 | 2004-10-21 | Nexmed (Holdings), Inc. | Prostaglandin compositions and their use for the treatment of vasospasm |
EP3141246A1 (en) * | 2009-08-31 | 2017-03-15 | Dr. Reddy's Laboratories Ltd. | Topical formulations comprising a steroid |
CN102091326B (zh) * | 2009-12-15 | 2013-04-03 | 上海凯茂生物医药有限公司 | 治疗因肛门皮下的静脉丛发生扩大或曲张所引发的痔类疾病的经皮给药制剂及制备方法 |
EP2693877A4 (en) * | 2011-04-07 | 2014-11-19 | Nexmed Holdings Inc | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
AU2013305563B2 (en) | 2012-08-24 | 2018-09-27 | Integurx Therapeutics, Llc | Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20160184431A1 (en) | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
US9561233B2 (en) | 2014-03-13 | 2017-02-07 | Demerx, Inc. | Use of ibogaine for the treatment of pain |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
ES2754353T3 (es) | 2014-05-23 | 2020-04-17 | Triple Hair Inc | Composiciones para reducir la caída del cabello y/o aumentar la regeneración del cabello |
US11696883B2 (en) | 2014-05-23 | 2023-07-11 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
BR112016029338A2 (pt) | 2014-07-29 | 2017-08-22 | Therapeuticsmd Inc | creme transdérmico |
US9592239B2 (en) | 2014-09-12 | 2017-03-14 | Demerx, Inc. | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake |
CA2958794C (en) | 2015-07-08 | 2018-10-23 | Triple Hair Inc. | Composition comprising resveratrol and melatonin for reducing hair loss and/or increasing hair regrowth |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US20170071874A1 (en) * | 2015-09-10 | 2017-03-16 | Tania Aranki | Topical analgesic |
GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
MX2018011705A (es) | 2016-04-01 | 2019-06-10 | Therapeuticsmd Inc | Composicion farmaceutica de hormona esteroide. |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
JP2020533283A (ja) | 2017-09-11 | 2020-11-19 | アトッサ セラピューティクス,インク. | エンドキシフェンを製造および使用する方法 |
WO2021003433A1 (en) | 2019-07-03 | 2021-01-07 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3731683A (en) * | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
US5304368A (en) * | 1993-02-19 | 1994-04-19 | American Telecast Corporation | Non-foaming, non-viscous, alcohol-free, water-based, pressurized hair spray product |
US5624060A (en) * | 1995-05-02 | 1997-04-29 | Ellion; M. Edmund | Invertible dispensing system and dip tube |
US6998138B2 (en) * | 1996-02-19 | 2006-02-14 | Acrux Dds Pty. Ltd. | Topical delivery of anti-alopecia agents |
US6916486B2 (en) * | 1996-02-19 | 2005-07-12 | Acrux Dds Pty Ltd | Transdermal delivery of analgesics |
US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US6916487B2 (en) * | 1996-02-19 | 2005-07-12 | Acrux Dds Pty Ltd | Transdermal delivery of antiemetics |
US7094422B2 (en) * | 1996-02-19 | 2006-08-22 | Acrux Dds Pty Ltd. | Topical delivery of antifungal agents |
US6923983B2 (en) * | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
FR2758479B1 (fr) * | 1997-01-20 | 1999-03-26 | Valois | Dispositif pour distribuer un produit fluide ou pulverulent a une distance predeterminee |
US20040044080A1 (en) * | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
US6113008A (en) * | 1998-08-20 | 2000-09-05 | 3M Innovative Properties Company | Actuator system for spraying a formulation onto a host |
EP1323430B1 (en) * | 2000-08-03 | 2007-03-14 | Antares Pharma IPL AG | Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
AUPR184500A0 (en) * | 2000-12-01 | 2001-01-04 | Drug Delivery Solutions Pty Ltd | Dispensing device |
US20050181032A1 (en) * | 2002-06-25 | 2005-08-18 | Acrux Dds Pty Ltd. | Metastable pharmaceutical compositions |
US20050186141A1 (en) * | 2002-06-25 | 2005-08-25 | Acrux Dds Pty Ltd. | Transdermal aerosol compositions |
KR20100055542A (ko) * | 2002-06-25 | 2010-05-26 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7700076B2 (en) * | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
FR2856301B1 (fr) * | 2003-06-23 | 2007-08-03 | Galderma Res & Dev | Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile |
DK1670433T3 (da) * | 2003-10-10 | 2012-03-12 | Ferring Bv | Transdermal farmaceutisk formulering til mindskelse af hudrester |
CN1886171A (zh) * | 2003-11-28 | 2006-12-27 | 艾克若克斯Dds有限公司 | 快速经皮施用的方法和系统 |
CN1889994A (zh) * | 2003-12-10 | 2007-01-03 | 艾克若克斯Dds有限公司 | 伴随透皮或局部药物输送的不希望的效果的治疗方法 |
PT2214643E (pt) * | 2007-11-02 | 2014-05-26 | Acrux Dds Pty Ltd | Sistema de entrega transdérmica para hormonas e esteroides |
-
2008
- 2008-09-11 AR ARP080103942A patent/AR068409A1/es unknown
- 2008-09-12 PE PE2008001595A patent/PE20091011A1/es not_active Application Discontinuation
- 2008-09-12 CL CL2008002720A patent/CL2008002720A1/es unknown
- 2008-09-12 US US12/209,864 patent/US20090098069A1/en not_active Abandoned
- 2008-09-12 WO PCT/US2008/076223 patent/WO2009036311A1/en active Application Filing
- 2008-09-12 CA CA2699630A patent/CA2699630A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2009036311A1 (en) | 2009-03-19 |
PE20091011A1 (es) | 2009-08-13 |
US20090098069A1 (en) | 2009-04-16 |
CA2699630A1 (en) | 2009-03-19 |
CL2008002720A1 (es) | 2008-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR068409A1 (es) | Composiciones farmaceuticas, transdermicas sin alcohol | |
ES2466676T3 (es) | Sistema de administración transdérmica para hormonas y esteroides | |
US20100292199A1 (en) | Transcutaneous pharmaceutical compositions containing a steroid hormone | |
JP6487949B2 (ja) | 局所用コルチコステロイド組成物 | |
JP2011502173A5 (es) | ||
US20060008432A1 (en) | Gilsonite derived pharmaceutical delivery compositions and methods: nail applications | |
US20160263067A1 (en) | Therapeutic Compositions | |
Schroeder et al. | Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs | |
EP1663142A2 (en) | Compositons and methods for topical administration | |
Singh et al. | Enhanced transdermal delivery of ketoprofen from bioadhesive gels. | |
JP2004051487A (ja) | 経皮吸収製剤 | |
EP1185246A1 (de) | Pharmazeutische zusammmensetzung zur nasalen anwendung von wasserunlöslichen und/oder schwer wasserlöslischen wirkstoffen | |
WO2009036355A1 (en) | Transdermal hormone spray | |
JP3418423B2 (ja) | 経粘膜投与用薬剤組成物 | |
JP5949285B2 (ja) | 貼付剤 | |
WO2019010230A1 (en) | COMPOSITIONS FOR DRUG DELIVERY | |
Castellano et al. | Chemical Enhancers | |
US20220079879A1 (en) | Emulsified gel composition | |
AU2016200691B2 (en) | Natural solubilizer agent comprising a synergistic blend of heptyl glucoside and olive oil glycereth-8 esters for transdermal compositions | |
DE19925290A1 (de) | Neue pharmazeutische Zusammensetzung zur nasalen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen | |
BE1021016B1 (nl) | Samenstelling voor de behandeling van nagelziektes en gebruik | |
Ning et al. | Delivery of risperidone from gels across porcine skin in vitro and in vivo in rabbits. | |
JPH06184000A (ja) | (−)−イソプレゴールからなる経皮吸収促進剤 | |
KR20070083272A (ko) | 피부 투과율이 개선된 안드로겐 함유 경피흡수용 겔 조성물 | |
US20040258724A1 (en) | Gilsonite derived pharmaceutical delivery compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |